ReviewOncoTargets and therapy2019
Research status and progress of the RNA or protein biomarkers for prostate cancer.
Review in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Accurate prognosis for localized prostate cancer through coherent voting networks with multi-omic and clinical data.Scientific reports · 2023Article
- Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.BMC medicine · 2020Article
- Differential expression profiles of circRNAs in human prostate cancer based on chip and bioinformatic analysis.International journal of clinical and experimental pathology · 2020Article
- FOXO1 and hsa-microRNA-204-5p affect the biologic behavior of MDA-MB-231 breast cancer cells.International journal of clinical and experimental pathology · 2020Article
- [Mass spectrometry-applications in pathology].Der Pathologe · 2019Review
- Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways.International journal of clinical and experimental pathology · 2019Article
- Noncoding RNAs Act as Tumor-Derived Molecular Components in Inducing Premetastatic Niche Formation.BioMed research international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a kind of male malignancy. Recently, a large number of studies have reported many potential biomarkers for the diagnosis and prognosis of prostate cancer. In this literature review, we have collected a number of potential biomarkers for prostate cancer reported in the last 5 years. Among them, some are undergoing Phase III clinical trials, and others have been approved by the US Food and Drug Administration. However, most are still in the period of basic research. The review will contribute to future research to find the biomarkers to guide clinicians to make personalized treatment decisions for each prostate cancer patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.